Buprenorphine And Naloxone

Introduction Overview

Generic Name

buprenorphine and naloxone

Brand Name

Suboxone

Dosage Form

buccal film, sublingual film, sublingual tablet

Drug Class

Narcotic analgesic combinations

Pharmacokinetics

Absorption:
Buprenorphine and naloxone in Suboxone are formulated for sublingual or buccal absorption, bypassing extensive first-pass metabolism that occurs when opioids are taken orally. After placement under the tongue or inside the cheek, the drugs dissolve and are rapidly absorbed through the oral mucosa into the systemic circulation. Peak plasma concentrations of buprenorphine occur approximately within 1 to 2 hours after sublingual dosing, with an onset of action typically within 20 to 60 minutes. Naloxone has very poor sublingual and buccal bioavailability, intentionally designed to limit systemic exposure and activation unless administered parenterally, which discourages misuse. Factors influencing absorption include the presence of saliva and whether the mouth is dry; patients are advised to moisten the mouth prior to administration to facilitate dissolution.

Distribution:
Buprenorphine is highly lipophilic and extensively distributed throughout body tissues, crossing the blood-brain barrier to exert its pharmacological effects in the central nervous system. It has an apparent volume of distribution of approximately 200 L, reflecting widespread tissue binding. Buprenorphine is approximately 96% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein, which influences free drug availability. Naloxone also distributes rapidly but has a lower volume of distribution due to its different physicochemical properties. Buprenorphine’s high affinity for mu-opioid receptors contributes to its long duration of action despite its relatively short plasma half-life.

Metabolism:
Buprenorphine is extensively metabolized primarily in the liver through the cytochrome P450 3A4 enzyme system (CYP3A4) via N-dealkylation to norbuprenorphine, an active metabolite with some opioid activity, though less potent. Further metabolism includes glucuronidation by UDP-glucuronosyltransferase enzymes (UGT1A1 and UGT2B7). Naloxone undergoes rapid hepatic metabolism mainly through conjugation pathways producing inactive metabolites. The combination drug's metabolism can be influenced by drugs that induce or inhibit CYP3A4, altering plasma concentrations and efficacy.

Elimination:
Buprenorphine and its metabolites are primarily eliminated via biliary excretion into feces, with approximately 10–30% of the total clearance occurring renally. The elimination half-life of buprenorphine ranges widely from 24 to 60 hours, contributing to its once-daily dosing schedule. Naloxone has a much shorter half-life of approximately 30 to 90 minutes when absorbed systemically but remains minimal after sublingual administration. Because of buprenorphine's prolonged half-life and depot effect at receptor sites, withdrawal symptoms may be attenuated and withdrawal onset delayed compared to full opioid agonists. Liver impairment can prolong elimination and requires cautious dosing.

Dosage Forms

Available Dosage Forms:
Suboxone is available in several specialized formulations optimized for sublingual or buccal administration to maximize absorption and minimize potential for misuse. These include:
- Sublingual film: containing buprenorphine/naloxone in combinations such as 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg.
- Buccal film: designed to be placed inside the cheek, also available in similar dosing strengths.
- Sublingual tablet: administered under the tongue, with strengths comparable to the films.

Dosages for Adults and Adolescents:
Induction phase dosing typically begins when moderate opioid withdrawal symptoms are present, and at least 6 hours after last opioid use to prevent precipitated withdrawal. Initial dose may be 2 mg/0.5 mg or 4 mg/1 mg, titrated every 2 hours with increments of 2 or 4 mg of buprenorphine up to 8 mg/2 mg on day 1. Day 2 dosing may increase up to 16 mg/4 mg. Maintenance treatment commences from day 3 onward, titrating doses to clinical effectiveness typically targeting 16 mg/4 mg daily with a maximum dose of 24 mg/6 mg per day.

Specific Patient Populations:
Induction with Suboxone sublingual tablets is not recommended; sublingual or buccal films are preferred for induction to minimize naloxone exposure during induction. Patients dependent on long-acting opioids (e.g., methadone) require buprenorphine monotherapy without naloxone for induction to avoid withdrawal. Dose adjustments in hepatic impairment are necessary due to altered metabolism and elimination. Pediatric and geriatric dosing should be individualized based on clinical response and tolerability. Pregnant women should use caution as buprenorphine monotherapy is generally preferred to minimize fetal exposure to naloxone.

Mechanism Of Action

Suboxone combines buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist, to treat opioid dependence effectively while deterring misuse. Buprenorphine exhibits high affinity and partial agonist activity at the mu-opioid receptor (MOR), producing sufficient opioid receptor activation to reduce withdrawal symptoms and cravings without eliciting the full opioid effect typical of full agonists. Its slow dissociation from the MOR and ceiling effect on respiratory depression contribute to its improved safety profile.

Naloxone, included primarily to deter intravenous misuse, has minimal sublingual/buccal bioavailability but acts as a competitive antagonist at opioid receptors when administered parenterally, quickly reversing opioid effects. If Suboxone is injected, naloxone precipitates withdrawal symptoms by displacing opioids from receptors, reducing abuse liability.

At the cellular level, buprenorphine activates G-protein coupled opioid receptors, modulating adenylate cyclase activity and calcium and potassium channels, decreasing neurotransmitter release and neuronal excitability, which mitigates withdrawal and craving. Unlike full agonists, buprenorphine’s partial agonism results in a plateau of opioid effects, reducing risk of respiratory depression and euphoria.

This combined mechanism allows Suboxone to stabilize opioid receptor activity in dependent patients, facilitating transition off full opioid agonists while minimizing abuse potential. Clinical studies demonstrate its effectiveness in improving retention in treatment programs and reducing illicit opioid use, establishing Suboxone as a cornerstone in medication-assisted therapy for opioid use disorder.

Pharmacological Actions

Partial agonist activity at mu-opioid receptors by buprenorphine, reducing opioid withdrawal symptoms.
Antagonist activity of naloxone at opioid receptors upon parenteral administration to prevent misuse.
Reduction of opioid craving and suppression of withdrawal symptoms in opioid-dependent individuals.
Ceiling effect on respiratory depression enhancing safety compared to full opioid agonists.
Modulation of neurotransmitter release via GPCR signaling pathways, influencing pain and reward circuits.
High receptor affinity and slow dissociation prolonging therapeutic effect and reducing dosing frequency.
Minimal systemic naloxone absorption upon sublingual administration to limit antagonistic effects during therapy.
Antagonism of illicit opioid-induced euphoria and respiratory depression in cases of relapse.
Prevention of significant opioid receptor activation upon misuse, decreasing abuse potential.
Stabilization of opioid receptor activity to facilitate maintenance therapy in opioid use disorder.
Reduction in peak plasma concentrations to avert opioid toxicity while maintaining efficacy.
Interaction with central nervous system pathways associated with mood and addiction behaviors.

Therapeutic Or Clinical Uses

Treatment of opioid dependence as part of a comprehensive treatment plan including counseling and psychosocial support.
Maintenance therapy to prevent relapse in patients with opioid use disorder.
Induction therapy following opioid withdrawal signs to transition patients from full opioid agonists.
Deterrent to intravenous opioid misuse through inclusion of naloxone.
Off-label use in certain cases for chronic pain management, although not FDA approved for pain.
Reduction of opioid cravings and withdrawal symptoms during detoxification.
Prevention of effects of illicit opioids, reducing risk of overdose and mortality.
Facilitation of long-term abstinence and rehabilitation from opioid addiction.
Integration into medication-assisted treatment protocols for opioid use disorder.
Supportive role in harm reduction strategies to decrease injection drug use risks.
Use in both inpatient and outpatient settings for opioid addiction management.
Management of patients transitioning from methadone or other long-acting opioids with cautious dosing.
Reduction of health care burden associated with opioid overdose and dependency.
Promotion of improved quality of life in opioid-dependent patients through symptom control.
Improvement in treatment adherence due to favorable pharmacokinetic and safety profiles.

Side Or Adverse Effects

Respiratory depression, particularly when combined with other CNS depressants or in overdose.
Withdrawal symptoms including sweating, shivering, diarrhea, runny nose, and muscle aches.
Allergic reactions such as hives, difficulty breathing, facial or throat swelling.
Oral complications including tongue pain, redness, numbness, tooth or gum problems.
Central nervous system effects: dizziness, drowsiness, blurred vision, impaired concentration.
Gastrointestinal symptoms: nausea, vomiting, constipation, loss of appetite.
Liver dysfunction signs: upper abdominal pain, dark urine, jaundice, clay-colored stools.
High serotonin syndrome risk when combined with serotonergic drugs: agitation, hallucinations, fever.
Low cortisol syndrome: nausea, vomiting, weakness, fatigue, dizziness.
Cardiovascular effects: tachycardia, palpitations, increased sweating.
Sleep disturbances including insomnia and abnormal dreams.
Confusion, loss of coordination, and extreme weakness potentially impacting safety.
Potential for abuse, addiction, and dependence, especially if misused.
Risks of fatal overdose particularly when combined with alcohol or sedative medications.
Serious breathing problems especially in elderly, debilitated, or patients with chronic pulmonary conditions.

Precautions

Avoid use if allergic to buprenorphine, naloxone, or any formulation component.
Use caution in patients with respiratory disorders such as sleep apnea or chronic obstructive pulmonary disease.
Screen for history of liver or kidney disease and monitor liver function regularly.
Vigilance in patients with prostate enlargement or urinary retention issues.
Careful assessment in those with neurological disorders including brain injury, tumors, or seizures.
Evaluate risk of substance abuse or history of addiction and counsel patients accordingly.
Avoid abrupt discontinuation to prevent precipitated withdrawal; taper under medical supervision.
Monitor for signs of serotonin syndrome when used concomitantly with serotonergic agents.
Warn patients about the risk of neonatal opioid withdrawal syndrome if used during pregnancy.
Instruct patients on proper sublingual/buccal administration techniques to ensure efficacy.
Ensure all healthcare providers are informed of Suboxone therapy for coordinated care.
Advise avoidance of alcohol and CNS depressants concomitantly to reduce risk of respiratory depression.
Supervise use in elderly or debilitated patients with comorbidities to prevent overdose.
Recommend regular dental checkups due to potential for oral mucosal irritation.
Ensure secure storage and proper disposal to prevent accidental ingestion or diversion.

Warnings

Risk of respiratory depression and potential respiratory arrest, especially with overdose or CNS depressant coadministration.
Potentially habit-forming with misuse leading to addiction, overdose, or death.
Fatal overdose risk if used by children or individuals without prescription.
Naloxone component may precipitate withdrawal if Suboxone is administered intravenously or in patients with recent methadone use.
Use during pregnancy may cause neonatal opioid withdrawal syndrome with life-threatening complications.
Concomitant use with alcohol, benzodiazepines, or other CNS depressants increases fatal overdose risk.
Serotonin syndrome risk when combined with serotonergic drugs, requiring immediate medical attention.
Do not crush or inject tablets or films as this practice has resulted in fatal outcomes.
Risk of liver injury necessitates liver function monitoring during therapy.
Abrupt stopping can precipitate withdrawal symptoms and relapse risk; tapering recommended.
Use with caution in patients with compromised respiratory function or head injuries.
May impair mental or physical abilities required for operating machinery or driving.
Contraindicated in patients with severe respiratory depression or acute intoxication.
Avoid sharing medication to prevent misuse and illegal distribution.
Store product out of reach of children and pets to prevent accidental ingestion.

Contraindication

Known hypersensitivity to buprenorphine, naloxone, or formulation ingredients.
Severe respiratory depression or acute bronchial asthma in an unmonitored setting.
Acute intoxication with alcohol, hypnotics, narcotics, centrally acting analgesics, or psychotropic drugs.
Use in patients with paralytic ileus or gastrointestinal obstruction.
Patients requiring opioid analgesics for pain as Suboxone is not indicated for analgesic use.
Children under 16 years of age due to safety and efficacy not established.
Concomitant use with other opioids that may precipitate withdrawal or increase adverse effects.
Use during pregnancy unless specifically advised and carefully managed by a specialist.
Concomitant use with monoamine oxidase inhibitors (MAOIs) within 14 days prior.
Patients with uncontrolled epilepsy or seizure disorders unless stabilized.
Any condition where opioid therapy is contraindicated or may exacerbate clinical status.
Severe hepatic impairment requiring dosage adjustment or avoidance.
Unsupervised patients at high risk of diversion or misuse.
Contraindicated for intranasal or intravenous misuse due to risk of precipitated withdrawal.
Known or suspected opioid intoxication without medical monitoring.

Drug Interactions

Increased risk of respiratory depression and sedation with concurrent use of benzodiazepines (e.g., diazepam, alprazolam, lorazepam).
Potential for opioid withdrawal symptoms if combined with full opioid agonists or methadone during induction.
Reduced effectiveness or enhanced toxicity when combined with CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics) altering buprenorphine metabolism.
Decreased buprenorphine plasma levels when administered with CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin), potentially reducing efficacy.
Increased risk of serotonin syndrome when used with serotonergic agents (e.g., SSRIs, SNRIs, triptans, MAOIs).
Additive CNS depressant effects with alcohol, antipsychotics, muscle relaxants, sleep agents, and some antidepressants.
Potential interaction with HIV medications such as protease inhibitors altering drug concentrations.
Concomitant use of opioid antagonists or partial agonists may precipitate withdrawal or reduce therapeutic effects.
Interaction with heart medications (e.g., calcium channel blockers, beta-blockers) potentially affecting pharmacodynamics.
Possible altered metabolism when taken with drugs treating hepatitis C (e.g., sofosbuvir, ledipasvir).
Co-administration with diuretics or medications for motion sickness or irritable bowel syndrome may enhance side effect profiles.
Use caution when combining with other CNS depressants such as antiepileptics or sedating antihistamines.
Interactions with herbal supplements (e.g., St. John’s Wort) affecting CYP enzymes and plasma levels.
Potential risks with medications affecting urinary bladder or prostate function.
Regular monitoring recommended when adding or discontinuing interacting drugs to adjust Suboxone dosing.

Preparations Of The Drug

Sublingual film strengths: 2 mg buprenorphine/0.5 mg naloxone, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg.
Buccal film formulations available in similar dosage strengths for placement inside the cheek.
Sublingual tablets formulated to dissolve under the tongue with dosages comparable to films.
Foil pouch packaging to protect films from moisture and preserve drug stability.
Single-use strips designed for ease of administration and to minimize diversion risk.
Formulations designed with naloxone to deter intravenous abuse, as naloxone becomes active if injected.
Replacement formulations such as Zubsolv and Bunavail offer alternative bioequivalent or bioavailable options.
Storage instructions emphasize room temperature, away from heat and moisture to maintain potency.
Disposal guidance includes removal from foil pack and flushing unused films to prevent accidental ingestion.
Manufactured under strict quality control to ensure consistent dosing and bioavailability.
Varied tablet and film sizes allow dose titration tailored to patient needs and treatment phases.
Produced with user-friendly design for patients requiring opioid dependence maintenance therapies.
Formulations intended for once-daily administration due to prolonged duration of buprenorphine activity.
Non-oral formulations such as injectable buprenorphine exist but are separate from Suboxone.
Distinct from buprenorphine monotherapy products used when naloxone is contraindicated.